World Monitor Magazine WM_November_2019_web | Page 39

EXPERT OPINION
Takeda is 3rd on
Kazakhstan's pharmaceutical
market
High inflation,
new products
• Cardiology
growth • Endocrinology
• Musculoskeletal
Growth in value
by 28,7%
In volume by 3.1 %
• Neurology
Growth Factors
in KZ Pharma Market by
• Gastroenterology
• Oncohematology
• Crohn's
disease
Growth in KZ Retail
Pharma
Market
•
Hemophilia
(YTD’07’19/ YTD’07’18)
KZT (trade prices), %
High inflation, new products
and structural c
-5,3%
growth
1,8%
Growth Factors in KZ Pharma Market by Channel
-0,5%
11,6%
Shonan Research Centre, our innovative park, now Shonan
iPark from 2018. This milestone brought us to the company's
next steps in the acquisition of several pharmaceutical and
research companies in specific therapeutic areas. For example,
in 2017, Ariad Pharmaceuticals was acquired with a strong
portfolio in oncology, and in 2019 the integration with Shire
happened. This step turned Takeda into the most significant
global biopharmaceutical player with R&D in its heart and
presence in more than 80 countries around the world. This
change reflected in almost every country of Takeda's presence.
Firstly, it is the largest purchase in the pharmaceutical business
– US $ 62 billion. Secondly, we appear in two world exchanges
– Tokyo and New York. We are the only pharmaceutical
company listed in both stocks. Thirdly, our business strategies
changed globally and in Kazakhstan too.
In Kazakhstan, we work in cardiology, endocrinology, diseases
of the musculoskeletal system, gastroenterology and
neurology. We focus on attracting innovations to Kazakhstan
in oncology, inflammatory bowel disease (IBD), such as Crohn's
disease and ulcerative colitis, hemophilia, rare diseases -
Hunter syndrome, Fabry and Gaucher diseases. Globally we
concentrate our attention in key therapeutic areas identified
as oncology, gastroenterology, rare diseases, neurology (and
a broader understanding of neuroscience – where mental
illnesses are also studied), as well as vaccines and plasma-
derived therapy. We keep the same path in Kazakhstan and
the cluster. Our innovations, like Entyvio and Adcetris, were
Growth in KZ Retail Pharma Market
(YTD’07’19/ YTD’07’18) Growth
(YTD’07
KZT (trade prices), % RZT (trad
-5,3%
8,3%
-0,5%
11,6%
1,8%
15,7%
8,3%
Inflation
Inflation
Structure
change
Structure index
Volume
change
index
growth
Volume
growth
Drop-out
New
8
products* produc
Drop-out
New
products* products*
Total
Growth
Infl
IQVIA Business breakfast, Kazakhstan, 24th September 2019
IQVIA Business breakfast, Kazakhstan, 24th September 2019
launched in 2015 and almost immediately we made them
available in Kazakhstan. The same thing is happening now
with rare diseases, where we work closely with the medical
community to identify the need for treatment and access
to medicine. More recently, factor VIII became available in
Uzbekistan for the treatment of hemophilia, and in Georgia,
we helped identify the first patients with Hunter syndrome. In
Kazakhstan, we are also actively working on Hunter syndrome,
using innovative technology for this work, conducted a
supported by EUROBAK
37